AXGN vs. CUTR, BLFS, ZYXI, OM, SMLR, EDAP, ELMD, FONR, VANI, and HYPR
Should you be buying AxoGen stock or one of its competitors? The main competitors of AxoGen include Cutera (CUTR), BioLife Solutions (BLFS), Zynex (ZYXI), Outset Medical (OM), Semler Scientific (SMLR), Edap Tms (EDAP), Electromed (ELMD), FONAR (FONR), Vivani Medical (VANI), and Hyperfine (HYPR). These companies are all part of the "electromedical equipment" industry.
Cutera (NASDAQ:CUTR) and AxoGen (NASDAQ:AXGN) are both small-cap computer and technology companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, valuation, risk, institutional ownership, profitability, community ranking, media sentiment and dividends.
Cutera has a beta of 1.42, indicating that its stock price is 42% more volatile than the S&P 500. Comparatively, AxoGen has a beta of 1.06, indicating that its stock price is 6% more volatile than the S&P 500.
90.7% of Cutera shares are held by institutional investors. Comparatively, 80.3% of AxoGen shares are held by institutional investors. 2.1% of Cutera shares are held by company insiders. Comparatively, 7.0% of AxoGen shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
AxoGen received 111 more outperform votes than Cutera when rated by MarketBeat users. Likewise, 72.48% of users gave AxoGen an outperform vote while only 64.85% of users gave Cutera an outperform vote.
AxoGen has a net margin of -12.99% compared to AxoGen's net margin of -73.42%. AxoGen's return on equity of 0.00% beat Cutera's return on equity.
In the previous week, Cutera had 3 more articles in the media than AxoGen. MarketBeat recorded 3 mentions for Cutera and 0 mentions for AxoGen. Cutera's average media sentiment score of 0.00 beat AxoGen's score of -0.33 indicating that AxoGen is being referred to more favorably in the news media.
Cutera presently has a consensus price target of $12.67, suggesting a potential upside of 559.72%. AxoGen has a consensus price target of $10.67, suggesting a potential upside of 53.04%. Given AxoGen's higher possible upside, research analysts clearly believe Cutera is more favorable than AxoGen.
AxoGen has lower revenue, but higher earnings than Cutera. AxoGen is trading at a lower price-to-earnings ratio than Cutera, indicating that it is currently the more affordable of the two stocks.
Summary
AxoGen beats Cutera on 11 of the 18 factors compared between the two stocks.
Get AxoGen News Delivered to You Automatically
Sign up to receive the latest news and ratings for AXGN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AXGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
